Increased depressive and anxiety-like behaviors are exhibited by rats and humans during withdrawal from psychostimulants. Anxiety-like behaviors observed during amphetamine withdrawal are mediated by increased expression and activity of corticotropin releasing factor type 2 (CRF 2 ) receptors in the dorsal raphe nucleus (dRN). Anxiety-like behavior of rats during withdrawal can be reversed by CRF 2 receptor antagonism in the dRN, but the efficacy of global central CRF 2 receptor antagonism is unknown. Rats were treated with amphetamine (2.5 mg/kg, ip.) or saline daily for 2 weeks, and were tested for anxietylike behaviors during withdrawal. Rats undergoing withdrawal showed increased anxiety-like behavior, which was reduced by ventricular infusion of the CRF 2 antagonist antisauvagine-30 (ASV 2 g/2 l). Surprisingly, ventricular ASV increased anxiety-like behavior in rats pre-treated with saline, but had an anxiolytic effect in un-treated rats. Western blots were performed to determine whether differences in CRF receptor densities could explain ASV-induced behavioral results. Saline pre-treated rats showed reduced CRF 1 receptor expression in the lateral septum compared to amphetamine pre-treated and untreated rats. Overall, these results suggest that central CRF 2 antagonism reduces anxiety states during amphetamine withdrawal, and that behavioral effects may be dependent upon the balance of CRF 1 and CRF 2 receptor activity in anxiety-related regions.
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Introduction
Anxiety and depression are major components of maintaining the cycle of addiction, and are responsible for the negative reinforcement of drug seeking behaviors (Sarnyai et al., 1995; Koob and Le Moal, 2008) . Both rats and humans exhibit increased anxiety states during withdrawal from amphetamine (Cantwell and McBride, 1998; Schuckit et al., 1999; Srisurapanont et al., 1999a,b; Srisurapanont, 2001; Romanelli and Smith, 2006; Shoptaw et al., 2009; Barr et al., 2010; Vuong et al., 2010) . There is currently no FDA-approved treatment for the negative affect and increased anxiety states exhibited during psychostimulant withdrawal, thus there is great need to identify potential pharmacological targets.
Abbreviations: 5-HT, serotonin; BNST, bed nucleus of the stria terminalis; aCSF, artificial cerebrospinal fluid; CeA, central nucleus of the amygdala; CRF, corticotropin-releasing factor; dRN, dorsal raphe nucleus; EPM, elevated plus maze; GABA, ␥-aminobutyric acid; LS, lateral septum; icv., intracerebroventricular.
* Corticotropin-releasing factor (CRF) is strongly implicated in negative affect and anxiety states (Radulovic et al., 1999; Takahashi, 2001; Bale and Vale, 2004; Bale, 2005; Lukkes et al., 2009b) . Activation of the CRF 2 receptors within the serotonergic cell body region, the dorsal raphe nucleus (dRN), increases serotonin neuronal activity and release of serotonin in the limbic system (Pernar et al., 2004; Forster et al., 2006 Forster et al., , 2008 Scholl et al., 2010) . Furthermore, CRF 2 receptors are up-regulated in the dRN of rats for up to 6 weeks of amphetamine withdrawal, with no change in expression of dRN CRF 1 receptors (Pringle et al., 2008) . Infusions of CRF into the dRN augments serotonin release in the central nucleus of the amygdala (CeA) of amphetamine pre-treated rats, as compared to CRF-infused controls, via CRF 2 receptor-dependent mechanisms (Scholl et al., 2010) . Importantly, anxiety-like behaviors of rats undergoing amphetamine withdrawal can be reduced by CRF 2 receptor antagonism directly within the dRN (Vuong et al., 2010) . Therefore, CRF 2 receptor antagonists may be important in the treatment of withdrawal-induced anxiety to prevent the ongoing cycle of addiction.
However, it is not known whether widespread antagonism of central CRF 2 receptors throughout the entire brain will be effective in reducing anxiety states during amphetamine withdrawal. This http://dx.doi.org/10.1016/j.neures.2014.08.010 0168-0102/© 2014 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.
